Abstract: A synthetic process for the preparation of amino acid esters such as methylphenidate and analogs thereof is disclosed. The process involves reacting an amino acid such as ?-phenyl-?-(2-piperidinyl)acetic acid or an analog thereof with an alcohol such as methanol in the presence of an acid and a water sequestrant such as trimethyl orthoacetate. In some embodiments, the water sequestrant is added to the reaction mixture after an initial period of esterification and then the reaction is allowed to continue. The ?-phenyl-?-(2-piperidinyl)acetic acid methyl ester or analog thereof is then isolated from the reaction mixture. In one variation of the process, the supernatant liquid may be recycled in subsequent runs to increase yield and product purity.
Type:
Grant
Filed:
January 6, 2010
Date of Patent:
October 9, 2012
Assignee:
Mallinckrodt LLC
Inventors:
Joseph P. Haar, Jr., Carl J. Schaefer, Charles S. Kuivila
Abstract: A contrast media injection system includes detects the absolute position of the syringe ram using a non-contact sensor. A series of magnets and Hall-Effect sensors may be used or an opto-reflective system. Illuminated knobs that are connected to the drive mechanism for the syringe ram rotate with the drive and provide visual feedback on operation through the illumination. Analog Hall-Effect sensors are used to determine the presence or absence of magnets that identify the type of faceplate being used. The faceplates include control electronics, connected to the powerhead through connectors, which may be interchangeably used by the two faceplates. The faceplate electronics include detectors for automatically detecting the capacity of pre-filled syringes.
Type:
Grant
Filed:
March 7, 2005
Date of Patent:
October 2, 2012
Assignee:
Mallinckrodt LLC
Inventors:
Jonathan D. Gibbs, John Kevin Bruce, Robert J. Ziemba, David M. Brooks, Gary S. Wagner
Abstract: The present invention provides processes for the synthesis of opiate alkaloids. In particular, the opiate alkaloids produced by the process of the invention are typically intermediate compounds that may be utilized to produce a variety of biologically active alkaloids including buprenorphine and diprenorphine.
Abstract: The present invention is generally directed to a process for the preparation of a ketomorphinan comprising maintaining a ketone group as unprotected and performing reductive amination using a hydrogen source and a catalyst.
Type:
Grant
Filed:
September 29, 2009
Date of Patent:
September 18, 2012
Assignee:
Mallinckrodt LLC
Inventors:
Edmund C. Hudson, Douglas Teramura, Christopher W. Grote, Catherine E. Thomasson, Gary L. Cantrell
Abstract: A pharmaceutical pig is used to transport a syringe containing a liquid radiopharmaceutical from a radiopharmacy to a medical facility for administration to a patient. The pharmaceutical pig includes an elongate polymer cap that is removably attached to an elongate polymer base. The elongate polymer cap includes a cap shell that completely encloses a cap shielding element and the elongate polymer base includes a base shell that completely encloses a base shielding element. Preferably the polymer utilized for the cap shell and the base shell is polycarbonate resin, e.g., LEXAN®. An inner liner is not utilized and the cap shielding element and the base shielding element, which are preferably, but not necessarily, made of lead, are completely sealed and unexposed.
Type:
Grant
Filed:
October 10, 2006
Date of Patent:
September 18, 2012
Assignee:
Mallinckrodt LLC
Inventors:
Frank M. Fago, Matt Bantly, David W. Wilson
Abstract: A syringe for an injector that has at its nozzle end a connection to the fluid delivery tubing that prevents, reduces, or eliminates fluid leaks, by virtue of a ridge on the external surfaces of the connector which engage to tubing. Furthermore, the syringe and injector are configured to permit the syringe to be oriented in more than one manner on the injector.
Abstract: A system and method are provided for reclaiming an enriched radioisotope starting material from a target body. The system and method enable reclaiming the starting material in a relatively short time (e.g., several hours) after the target body's bombardment with energetic particles, greatly simplifying the target body's chemical processing, as well as reducing the cost of such processing (e.g., reducing the need for costly long-term storage). Specifically, a chemical protective layer is disposed between a radioisotope starting material and a base material of the target body. After the target body is irradiated with a suitable source (e.g., particle accelerator), then the irradiated radioisotope starting material can be removed without removing the base material due to the protection provided by the chemical protective layer. The system and method also enable the operator to obtain three different radioisotopes in a single bombardment of the target body, further reducing cost of radioisotope production.
Abstract: An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patent who is then diagnosed or treated using the effector molecule.
Abstract: A contrast media injection system includes detects the absolute position of the syringe ram using a non-contact sensor. A series of magnets and Hall-Effect sensors may be used or an opto-reflective system. Illuminated knobs that are connected to the drive mechanism for the syringe ram rotate with the drive and provide visual feedback on operation through the illumination. Analog Hall-Effect sensors are used to determine the presence or absence of magnets that identify the type of faceplate being used. The faceplates include control electronics, connected to the powerhead through connectors, which may be interchangeably used by the two faceplates. The faceplate electronics include detectors for automatically detecting the capacity of pre-filled syringes.
Type:
Grant
Filed:
April 14, 2010
Date of Patent:
August 28, 2012
Assignee:
Mallinckrodt LLC
Inventors:
Charles S. Neer, Robert J. Ziemba, David M. Brooks, James R. Small
Abstract: The invention generally provides processes and intermediate compounds useful for the production of (+)-opiates. Non-limiting examples of (+) opiates that may be derived from one or more compounds of the invention include (+)-noroxymorphone, (+)-naltrexone, (+)-naloxone, (+)-N-cyclopropylmethylnorhydrocodone, (+)-N-cycloproylmethylnorhydromorphone, (+)-N-allylnorhydrocodone, (+)-N-allylnorhydromorphone, (+)-noroxycodone, (+)-naltrexol, (+)-naloxol, and (+)-3-O-methyl-naltrexone.
Type:
Grant
Filed:
December 17, 2008
Date of Patent:
August 28, 2012
Assignee:
Mallinckrodt LLC
Inventors:
Peter X. Wang, Tao Jiang, Gary L. Cantrell, David W. Berberich, Bobby N. Trawick, Todd Osiek, Subo Liao, Frank W. Moser, Joseph P. McClurg
Abstract: The present invention provides processes for the synthesis of five and six membered rings. In particular, the present invention provides processes for the synthesis of five and six membered rings in alkaloids.
Type:
Grant
Filed:
September 14, 2009
Date of Patent:
August 28, 2012
Assignee:
Mallinckrodt LLC.
Inventors:
Peter X. Wang, Tao Jiang, David W. Berberich
Abstract: An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patent who is then diagnosed or treated using the effector molecule.
Abstract: The present invention is directed to processes for the synthesis of morphinans. In particular, a process for the asymmetric reduction of an imine moiety in a 3,4-dihydroisoquinoline to produce a tetrahydroisoquinoline, followed by a Birch reduction to produce a hexahydroisoquinoline. In various embodiments, the 3,4-dihydroisoquinoline contains a phenol moiety protected with a labile protecting group. In other embodiments, the imine reduction reaction mixture contains silver tetrafluoroborate.
Type:
Grant
Filed:
December 10, 2007
Date of Patent:
August 14, 2012
Assignee:
Mallinckrodt LLC
Inventors:
Gary L. Cantrell, Dan P. Magparangalan, Frank W. Moser, Jian Bao, Christopher W. Grote, Peter X. Wang
Abstract: This invention is directed to non-benzenoid aromatic compounds. Other aspects include methods of using non-benzenoid aromatic compounds for imaging and phototherapeutic uses thereof. Non-benzenoid compounds provided herein generally have one or more substituent groups which allow tailoring of the spectral properties or provide photoreactivity or targeting ability.
Abstract: The present invention is directed to processes for the synthesis of morphinans. In particular, a process for coupling a carboxylic acid compound with an amine compound to form an amide product that can then be isolated or the crude amide product can be cyclized to form a 3,4-dihydroisoquinoline. In one embodiment, the carboxylic acid contains a phenol moiety protected with a labile protecting group. The protected phenol reduces reaction times, simplifies work-up of the product, and reduces the amount of cyclizing agent, POCl3 that is necessary to form the 3,4-dihydroisoquinoline.
Type:
Grant
Filed:
June 10, 2009
Date of Patent:
July 31, 2012
Assignee:
Mallinckrodt LLC
Inventors:
Peter X. Wang, Frank W. Moser, Christopher W. Grote, Gary L. Cantrell
Abstract: The present invention provides processes for the production of opiate alkaloids. In particular, the present invention provides processes for increasing the yield of opiate alkaloids by introducing at least one recycling step.
Abstract: The invention provides processes for the production of opiate alkaloids. In particular, the present invention provides processes for the formation of opiate alkaloids that minimizes the formation of impurities.
Abstract: The present invention provides process for the production of opiate alkaloids. In particular, the present invention provides processes for the production of buprenorphine or a derivative of buprenorphine that minimizes the formation of impurities.
Type:
Grant
Filed:
September 29, 2009
Date of Patent:
July 31, 2012
Assignee:
Mallinckrodt LLC
Inventors:
Brenda E. Allen, Esa T. Jarvi, Dennis J. Kalota, James R. Meyer, Keith G. Tomazi, Anthony Mannino, Brian Orr
Abstract: Disclosed herein are embodiments of a radiation shielding lid of a radiation shielding container (e.g., auxiliary radiation shield) designed to house a radioisotope generator assembly.
Type:
Application
Filed:
July 19, 2011
Publication date:
July 26, 2012
Applicant:
Mallinckrodt LLC
Inventors:
Scott Hayward Mayfield, Kevin Robert Martz